1. Office USGA. Drug development: FDA’s priority review voucher programs. 2020 Jan 31 [cited 2021 Jan 28]; (GAO-20-251). Available from: https://www.gao.gov/products/GAO-20-251.
2. 2020 Healthcare investments & exits report [Internet]. [cited 2021 Jan 28]. Available from: https://www.svb.com/trends-insights/reports/healthcare-investments-and-exits/2020-annual
3. Trends in healthcare investments and exits, Mid Year 2020 | Silicon Valley Bank [Internet]. [cited 2021 Jan 28]. Available from: https://www.svb.com/trends-insights/reports/healthcare-investments-and-exits/2020-mid-year.
4. How orphan drugs became a highly profitable industry [Internet]. The Scientist Magazine®. [cited 2021 Jan 28]. Available from: https://www.the-scientist.com/features/how-orphan-drugs-became-a-highly-profitable-industry-64278.
5. Thomas D, Wessel C. BIO emerging therapeutics company investment and deal trends report 2008–2017.pdf [Internet]. Biotechnology Industry Organization; 2018 [cited 2020 Jan 28]. Available from: http://go.bio.org/rs/490-EHZ-999/images/BIO%20Emerging%20Therapeutics%20Company%20Investment%20and%20Deal%20Trends%20Report%202008-2017.pdf?_ga=2.198662575.1692623197.1611889295-1576093676.1611889295.